Repeat procedures
ERCP with sphincterotomy or dilation is the default for functional biliary pain, yet relief is often temporary and post-ERCP pancreatitis remains the most common serious complication.
Clinical-stage biotechnology · Newport Beach, California
Relief for the pain that surgery leaves behind.
Discovery begins with one.
Maison Blaise Labs is developing a receptor-targeted, non-surgical approach to post-cholecystectomy syndrome, functional biliary pain, and opioid-sparing visceral pain relief, supported by pending U.S. and international patent applications and advancing toward a two-site Southern California clinical study.
Our lead program is investigational. Nothing on this site is medical advice or a claim of safety or efficacy for any marketed product.
1.2M+Gallbladder removals performed each year in the U.S. StatPearls
5–47%Of patients experience post-cholecystectomy syndrome Merck Manual
500KERCP procedures annually in the U.S., with pancreatitis in up to 10–15% PMC
2Published patent applications, U.S. and PCT (October 2026), from a 73-claim priority filing
The problem
After the gallbladder is gone, the pain often is not.
For a meaningful share of the more than a million people who undergo cholecystectomy each year, right-upper-quadrant pain, abnormal liver enzymes, and biliary spasm continue or return. Today's options are repeat endoscopic procedures, sphincterotomy, or long-term opioids, each carrying real risk and none addressing the underlying signaling.
Opioid reliance
Chronic visceral pain is a leading reason for long-term opioid use. Opioid prescribing for chronic abdominal pain in U.S. clinics more than doubled over a decade.
Liver at risk
Recurrent biliary obstruction and spasm drive elevated ALT/AST, hepatomegaly, and over time, fibrosis. Patients cycle through labs, imaging, and hospital visits without resolution.
Our science
Targeting hidden pathways. Restoring natural balance.
Our platform centers on precision modulation of GLP-1 and GIP receptor signaling, pathways long known for their metabolic role, and now showing potential in bile flow regulation, sphincter smooth-muscle tone, vagal signaling, and non-opioid pain relief.
- A real-world signal
The program began with a documented patient case of post-cholecystectomy biliary dysfunction in which sustained receptor agonism was followed by complete pain resolution, normalization of severely elevated liver enzymes, and no further ERCP, surgery, or opioid therapy.
- A mechanistic rationale
GLP-1 is derived from the same proglucagon precursor as glucagon, the agent endoscopists use to relax the biliary sphincter. Receptors on vagal afferents and brainstem nuclei offer a parallel route to dampen visceral pain signaling.
- Proprietary methods of use supported by pending patent applications
We filed in April 2025 and now hold published U.S. and international (PCT) patent applications directed to methods of treating post-cholecystectomy syndrome, sphincter of Oddi dysfunction, biliary dysfunction, and related pain. No patent has yet been granted.
- A path to evidence
A two-site prospective study in Southern California is being designed to measure liver enzymes, pain scores, procedure avoidance, and opioid use over 12 weeks.
Targeted systems
One receptor class. Four interacting systems.
01
Gut–brain axis
Receptor signaling that links the digestive tract to pain-processing centers in the brainstem, a route to calming visceral hypersensitivity.
02
Biliary & hepatobiliary flow
Relaxation of the biliary sphincter and support of bile drainage, with the potential to normalize liver enzymes without a procedure.
03
Neural pain modulation
Central and peripheral dampening of pain signaling that may reduce reliance on opioids in chronic abdominal and visceral pain.
04
Vagus nerve signaling
Vagal afferent pathways that carry gut signals to the brain and may be dysregulated after surgery, chronic inflammation, or nerve injury.
Clinical research
A two-site Southern California study, now in planning.
We are preparing an IRB-reviewed, prospective study of a dual GLP-1/GIP receptor agonist prescribed under physician care in adults with post-cholecystectomy syndrome, functional biliary pain, and liver enzyme abnormalities. Planned sites are an academic medical center in San Diego and a clinical site in Orange County, each enrolling approximately 50 participants.
Enrollment has not yet opened. Registering interest is voluntary and non-binding; it does not guarantee eligibility or participation, and your information is used only to contact you about the study.
Study at a glance
- Design: prospective, open-label, 12 weeks, two sites, ~100 participants
- Who may qualify: adults 18–75 with prior cholecystectomy and recurrent right-upper-quadrant pain, with or without elevated ALT/AST
- What is measured: liver enzymes, weekly pain scores, GI symptom diary, opioid use, procedures avoided, adverse events
- Visits: baseline labs, weekly virtual or in-person check-ins, final visit with labs at week 12
- Oversight: institutional review board approval at each site before any enrollment
Pipeline & intellectual property
A multi-indication receptor platform, supported by pending patent applications.
Our lead program addresses post-cholecystectomy syndrome and functional biliary disorders. The same biology opens adjacent indications in opioid-sparing visceral pain, vagal dysregulation, and gut–brain hypersensitivity.
Program I
Potential use of GLP-1/GIP receptor agonism in functional biliary disorders
StatusObservational study design · IRB submissions pending · IND exemption requested
Lead indication: post-cholecystectomy syndrome, sphincter of Oddi dysfunction and related liver enzyme abnormalities. Two Southern California sites, approximately 100 participants, 12-week primary endpoint.
Future indications
- Opioid-sparing treatment of chronic visceral pain
- Visceral hypersensitivity syndromes
- Vagal nerve dysregulation
- Non-biliary post-surgical pain syndromes
| Publication | Title | Status |
|---|---|---|
| US 2026/0306588 A1Appl. No. 19/637,850 | Compositions and uses of GLP-1-GIP receptor agonists | Published Oct 8, 2026 · Track One examination |
| WO 2026/213436 A1PCT/US2026/022119 | Compositions and uses of GLP-1-GIP receptor agonists | Published Oct 8, 2026 |
| Priority | U.S. Provisional 63/783,912 | Filed Apr 4, 2025 |
Applicant: Maison Blaise Labs, LLC. Patent applications are pending; no patent has yet been granted.
- Apr 2025Provisional patent filedMethod-of-use claims for post-cholecystectomy syndrome, SOD, and biliary pain
- Apr 2026U.S. non-provisional and PCT filedPrioritized (Track One) examination requested and granted May 2026
- Oct 2026U.S. and international publicationClaims under active examination with the USPTO
- Q4 2026IRB submissions at two Southern California sitesProtocol, consent, and data-collection framework finalized
- 2027Enrollment and 12-week follow-upTarget ~100 participants; interim analysis at 50% enrollment
Partnering
Licensing, co-development, and research collaboration.
Maison Blaise Labs welcomes inquiries for licensing, co-development, and clinical data sharing from biopharma, health systems, and academic research groups, covering our lead program and the broader multi-indication platform. Discussions beyond public information take place under a confidentiality agreement.
Biopharma
Exclusive field licensing or co-development of a new indication for an established receptor-agonist class, supported by pending method-of-use patent applications and prospective clinical data.
Health systems & clinical sites
Site participation in our prospective study, investigator roles, and real-world data collaboration for a patient population that is frequent, costly, and under-served.
Academic research
Mechanistic and translational collaboration on gut–brain signaling, biliary motility, and vagal modulation of visceral pain, with co-authorship and publication as shared goals.
About
Patient-originated. Physician-supported. Built to scale.
Our founder lived for over a decade with recurrent right-upper-quadrant pain after cholecystectomy, diagnosed with Type III sphincter of Oddi dysfunction, treated with four ERCPs, balloon dilations, and sphincterotomies, and still in pain. When she pursued a theory about receptor signaling and biliary spasm, the result was a complete resolution of symptoms and normalization of liver enzymes that has now persisted for more than two years.
Rather than keep that insight as a personal story, she documented it, filed patent applications on it, and is now putting it to a rigorous test. Maison Blaise Labs exists to turn patient-originated discovery into targeted, non-invasive therapies.
The heart has its reasons, which reason does not know.
Discovery begins with one.Our values · Real-world validation · Integrity in intellectual property · Platforms that scale across systems
Contact
Let's talk.
Based in Newport Beach, California. We respond to every serious inquiry.
Clinical sites & investigators
Physician referrals and site participation.
clinical@maisonblaiselabs.com